AlphaGrep UK
PTCT icon

AlphaGrep UK’s PTC Therapeutics PTCT Stock Holding History

AlphaGrep UK’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$205K Buy
+3,169
New +$231K 0.06% 673

Other funds holding PTCT

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $33.9B AUM 47.7% 1-Year Est. Return

AlphaGrep UK's PTCT Position: Q3 2026 in Review

AlphaGrep UK opened a new position in PTC Therapeutics (PTCT) in Q3 2026: 3,169 shares worth $205K. The stake represents 0.06% of the portfolio and ranks #673 among its holdings.

275 funds tracked by Wall St. Rank hold PTCT as of Q3 2026.

  • AlphaGrep UK held 3,169 shares of PTC Therapeutics worth $205K as of Q3 2026.
  • PTC Therapeutics was a new AlphaGrep UK position in Q3 2026.
  • PTC Therapeutics made up 0.06% of AlphaGrep UK's portfolio in Q3 2026, its #673 holding.
  • 275 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2026.

Based on AlphaGrep UK's 13F filing for Q3 2026, filed 12 Nov 2026.